Regulation

Category 1, 2, 3:
what they mean.

Most “peptide is legal now” headlines come down to a list most people have never read. Here is how it works.

Short answerRegulation · 5 min read · Updated 17 Nov 2026

The categories belong to FDA's interim policy for bulk substances that compounding pharmacies may use under Section 503A. Category 1 substances are under evaluation and may be compounded in the meantime. Category 2 substances raise significant safety concerns and should not be. Category 3 substances were nominated without enough supporting information. None of the categories is an approval.

01What are FDA Category 1, 2 and 3 peptides?

The categories belong to FDA's interim policy for bulk substances that compounding pharmacies may use under Section 503A.

Category 1

Nominated with enough information to evaluate, no identified significant safety risk. May be compounded while FDA decides.

Category 2

Raises significant safety risks. FDA intends to act against compounders using them.

Category 3

Nominated without adequate supporting information. Cannot be evaluated until resubmitted.

02When can a bulk substance be used in 503A compounding?

A bulk substance can lawfully be used in 503A compounding only if it meets one of three tests.

1
It has a USP or NF monograph

A published compendial standard.

2
It is a component of an approved drug

Already part of an FDA-approved product.

3
It is on the 503A bulks list

Added through notice-and-comment rulemaking after advisory-committee review.

03Does leaving Category 2 mean a peptide is approved?

No. In April 2026 twelve peptides left Category 2 after their nominations were withdrawn. That removed a red flag; it did not move them into Category 1 or onto the bulks list.

In July 2026 the advisory committee recommended six of them for the bulks list. That is advice, not a listing. In October 2026 HHS issued an interim enforcement-discretion policy for those six while rulemaking continues. Each step matters; none of them is FDA approval.

042026 status at a glance

PeptideCategory 2 (2023)Left Category 2 (Apr 2026)PCAC (Jul 2026)HHS interim policy (Oct 2026)
BPC-157YesYesRecommendedCovered
TB-500YesYesRecommendedCovered
KPVYesYesRecommendedCovered
MOTS-cYesYesRecommendedCovered
SemaxYesYesRecommendedCovered
EpitalonYesYesRecommendedCovered
DSIP (emideltide)YesYesNot recommended (press-reported)Not covered

RefSources

  1. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A. Interim policy and category lists. www.fda.gov/drugs/human-drug-compounding/bulk-drug-substanc…
  2. Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings. 16 April 2026. www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of…
  3. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. April 2026. www.frierlevitt.com/articles/fda-peptides-do-not-compound-l…
  4. National Law Review. FDA Committee Supports Peptide Compounding: What Comes Next. July 2026. natlawreview.com/article/fda-committee-supports-peptide-com…
  5. Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. 30 October 2026. www.foley.com/?p=130749
  6. AJMC. HHS Draft Policy Eases Enforcement on 6 Compounded Peptides. 29 October 2026. www.ajmc.com/view/hhs-draft-policy-eases-enforcement-on-6-c…

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Is BPC-157 Category 1 now?

Leaving Category 2 is not the same as entering Category 1. The relevant 2026 changes are the PCAC recommendation and the interim HHS policy; permanent status depends on rulemaking.

Who decides the final list?

FDA, through notice-and-comment rulemaking, after consulting the Pharmacy Compounding Advisory Committee.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Every batch has a public lab report. Look it up by the batch number on the vial. Batch COA lookup